TD Asset Management
ALLO icon

TD Asset Management’s Allogene Therapeutics ALLO Stock Holding History

TD Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.59M Buy
652,484
+238,410
+58% +$478K ﹤0.01% 1014
2025
Q4 		$567K Hold
414,074
– – ﹤0.01% 1158
2025
Q3 		$513K Sell
414,074
-131,314
-24% -$157K ﹤0.01% 1169
2025
Q2 		$616K Hold
545,388
– – ﹤0.01% 1111
2025
Q1 		$796K Hold
545,388
– – ﹤0.01% 1100
2024
Q4 		$1.16M Sell
545,388
-131,752
-19% -$325K ﹤0.01% 1095
2024
Q3 		$1.97M Sell
677,140
-122,200
-15% -$326K ﹤0.01% 1052
2024
Q2 		$1.86M Buy
799,340
+361,904
+83% +$1.07M ﹤0.01% 1024
2024
Q1 		$1.96M Buy
437,436
+199,600
+84% +$833K ﹤0.01% 1031
2023
Q4 		$763K Hold
237,836
– – ﹤0.01% 1236
2023
Q3 		$754K Buy
237,836
+38,357
+19% +$168K ﹤0.01% 1196
2023
Q2 		$991K Buy
199,479
+25,800
+15% +$140K ﹤0.01% 1134
2023
Q1 		$858K Hold
173,679
– – ﹤0.01% 1163
2022
Q4 		$1.09M Buy
173,679
+9,000
+5% +$83.3K ﹤0.01% 1125
2022
Q3 		$1.7M Buy
164,679
+36,706
+29% +$499K ﹤0.01% 1053
2022
Q2 		$1.46M Buy
127,973
+5,600
+5% +$49.7K ﹤0.01% 1098
2022
Q1 		$1.11M Buy
122,373
+13,200
+12% +$137K ﹤0.01% 1212
2021
Q4 		$1.63M Sell
109,173
-2,192
-2% -$38.7K ﹤0.01% 1180
2021
Q3 		$2.86M Buy
111,365
+19,689
+21% +$467K ﹤0.01% 977
2021
Q2 		$2.01M Buy
91,676
+10,171
+12% +$290K ﹤0.01% 1094
2021
Q1 		$2.88M Buy
81,505
+3,632
+5% +$123K ﹤0.01% 995
2020
Q4 		$1.97M Buy
77,873
+192
+0.2% +$6.26K ﹤0.01% 1043
2020
Q3 		$2.93M Sell
77,681
-4,800
-6% -$181K ﹤0.01% 829
2020
Q2 		$3.53M Buy
82,481
+28,206
+52% +$1.02M 0.01% 735
2020
Q1 		$1.05M Sell
54,275
-3,600
-6% -$85.8K ﹤0.01% 981
2019
Q4 		$1.5M Hold
57,875
– – ﹤0.01% 995
2019
Q3 		$1.58M Hold
57,875
– – ﹤0.01% 961
2019
Q2 		$1.55M Buy
57,875
+32,232
+126% +$898K ﹤0.01% 967
2019
Q1 		$741K Buy
25,643
+600
+2% +$17.4K ﹤0.01% 1099
2018
Q4 		$674K Buy
+25,043
New +$665K ﹤0.01% 1154

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TD Asset Management's ALLO Position: Q1 2026 in Review

TD Asset Management increased its Allogene Therapeutics (ALLO) stake by 58% in Q1 2026, buying an estimated $478K and bringing the position to 652,484 shares worth $1.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1014.

TD Asset Management first reported a position in ALLO in Q4 2018 and has held it in 30 quarters since. The position peaked at $3.53M in Q2 2020. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • TD Asset Management held 652,484 shares of Allogene Therapeutics worth $1.59M as of Q1 2026.
  • TD Asset Management bought 238,410 Allogene Therapeutics shares in Q1 2026, an estimated $478K.
  • Allogene Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #1014 holding.
  • TD Asset Management first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 30 quarters since.
  • TD Asset Management's Allogene Therapeutics position peaked at $3.53M in Q2 2020.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.